navitoclax,ruxolitinib
abbvie
['refine ', 'mpnsm', '#mpn', 'leusm', 'navitoclax']
#asco22 #leusm #mpnsm menghrajani: navitoclax + rux shown to have promise in ph2 study in those with pd or poor resp to jaki. here, preliminary data from frontline navitoclax + rux ph2 refine study show good spleen size redxn responses; thrombocytopenia an issue (47% gr3+). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)